Long
AXNX Breaks Out of IPO Range
AXNX big range break today for the recent IPO, $435M maker of sacral neuromodulation solutions for overactive bladders and urinary retention. AXNX presented positive data this morning and will report on 3-5. It is an early-stage med-tech Co. with $6.9M in revenues seen for 2019 but forecasts calling for $200M+ by 2022.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.